Bayer's pharma head Dieter Weinand talks about his biggest issues with current value-based pricing assessments for new drugs and how companion diagnostics will pave the way to easier pricing of oncology therapies.
Bayer AG's head of pharma Dieter Weinand has warned the pharma industry it should act now to help broaden thinking and remove silos related to value-based assessments for new drugs, if it wants to unlock the next scientific revolution arising from breakthroughs like CRISPR gene editing.
"We are on the cusp of the next scientific revolution and we need to figure out how, comprehensively and long-term,...
Create an account to read this article
Already a subscriber?
The Swiss giant has been talking to the US government about selling medicines directly to patients.
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.
Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.
Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.
